Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Hematology
• Hepatic
• Leukemia
• Lung
• Lymphoma
• Melanoma
• Myelomas
• Ovarian
• Pancreatic
• Prostate
• Renal
• Solid Tumors

 

Bladder

• A study of Enfortumab Vedotin for urothelial cancer

  A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
  

  ---

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• Adjuvant Giredestrant compared w/Physician’s choice in patients with ER+, HER2- early breast cancer

  A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
  

  ---

• A study of Abemaciclib + ET in patients with HR+, HER2+ early breast cancer

  A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (I3Y-MC-JPCW)
  

  ---

• A Study of treatments in Her2+ first line metastatic breast cancer

  A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
  

  ---

• A Phase 3 study of LY3484356 vs Investigator’s choice of endocrine therapy in Breast Cancer

  A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
  

  ---

• A Phase IB/II study of durvalumab + datopotamab deruxtecan in Breast Cancer

  A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
  

  ---

• Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
  

  ---

• Phase 1a/1b Study of LY3484356 in Metastatic Breast Cancer Patient

  A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
  

  ---

• Phase 2 of Tucatinib in Combination with Trastuzumab Deruxtecan

  A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
  

  ---

Colon

• A Phase 3 study of MRTX849 + Cetuximab vs. Chemotherapy in Colorectal Cancer

  A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
  

  ---

• Phase 3 Study of Olaparib in Metastatic Colorectal Cancer Patients

  A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab
  

  ---

• Phase 3 Trilaciclib/Placebo in Metastatic Colorectal Cancer

  A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
  

  ---

• Phase 3b for MSI-H or MMR Colorectal Cancer Patients

  A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
  

  ---

Gastrointestinal

• Phase 3 Study of INCMGA00012 in Anal Cancer

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

• Phase 3 Study of Sintilimab in Esophageal Cancer

  A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
  

  ---

Hematology

• A Phase 2 study of Selinexor vs Physician’s choice in patients with Myelofibrosis

  A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIANíS CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS
  

  ---

• Phase 3 Study of Navitoclax in Myelofibrosis

  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
  

  ---

• Phase 3 Study of Pacritinib in Severe Thrombocytopenia

  A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia
  

  ---

Hepatic

• Phase 2 Study of MK-1308A + Lenvatinib in First Line Hepatocellular Cancer

  A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (MK1308/MK3475) in Combination with Lenvatinib (E7080/MK7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
  

  ---

Leukemia

• Phase IIIb study of Asciminib in patients with CML

  An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
  

  ---

• Phase 3 study of LOXO-305 vs. Investigator’s choice in BTK Inhibitor pretreated CLL/SLL

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• A Phase 3b Study of asciminib chronic myeloid leukemia

  An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
  

  ---

• Phase 3 Study of LOXO-305 in CLL/SLL Patients

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• Phase 2 Study of Ublituximab in Combination with Umbralisib and Venetoclax for CLL patients

  Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia
  

  ---

• Phase III of Obinutuzumab and Venetoclax in Untreated CLL without 17p deletion or Tp53 mutation

  A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION
  

  ---

Lung

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

• Phase 2 Study of RMC-4630 and Sotorasib for NSCLC patients with KRAS G12C mutation

  A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
  

  ---

• Phase 3 Study of Selpercatinib in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• A Phase III study of capmatinib + osimertinib vs platinum chemo in patients with NSCLC

  A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st / 2nd generation EGFR‑TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification
  

  ---

• A Phase 3 study of subcutaneous Pembrolizumab vs. Chemo in Lung Cancer

  A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer
  

  ---

• A Phase 3 study of Adjuvant Selpercatinib in lung cancer

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• Phase 2 Study of VS-6766 +/- Defactinib in Lung Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of MRTX849 in Lung Cancer

  A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
  

  ---

• Phase 3 Study of Amivantamab and Lazertinib in Lung Cancer

  A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Amivantamab in Lung Cancer

  A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 2 Study of AB122 and AB154 in Front Line Non-Small Cell Lung Cancer Patients

  A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
  

  ---

• Phase 1/2 Study of NKTR-214 in Patients with Locally Advanced/Metastatic Solid Tumors

  
  

  ---

Lymphoma

• Zanubrutinib in Patients w/previously treated B-Cell Lymphoma

  A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 
  

  ---

• Phase 3 study of LOXO-305 vs. Investigator’s choice in BTK Inhibitor pretreated CLL/SLL

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• A Phase 1 study of NKTR-255 in relapsed or refractory hematological malignancies

  A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
  

  ---

• A trial of Tazemetostat + Rituximab in subjects w/Follicular Lymphoma

  A PHASE II OPEN-LABEL, MULTICENTER TRIAL OF ORAL TAZEMETOSTAT IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
  

  ---

• Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL

  A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma
  

  ---

• Phase 3 Study of Acalabrutinib in Untreated Diffuse Large B-Cell Lymphoma

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  

  ---

• Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

Melanoma

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

• Phase 3 Study of Adjuvant Immunotherapy in Melanoma Patients

  A Phase 3, Randomized, Open-label Study of Adjuvant Immunotherapy with Bempegaldesleukin with Nivolumab Versus Nivolumab after Complete resection of Melanoma in Participants at High Risk for Recurrence
  

  ---

Myelomas

• A Phase 1 study of NKTR-255 in relapsed or refractory hematological malignancies

  A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
  

  ---

Ovarian

• Phase 2 Study ofVS-6766 +/- Defactinib in Ovarian Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
  

  ---

Pancreatic

• Phase 2 Study of SBRT with GC4711 for Unresectable, Non-Metastatic Pancreatic Cancer

  A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
  

  ---

Prostate

• A Phase 2/3 study of Abiraterone Acetate + Prednisone +/- Abemaciclb in prostate patients

   A Phase 2/3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
  

  ---

• Phase III study comparing 177Lu-PSMA-617 vs. change of androgen receptor-therapy in prostate pts

  A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naīve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
  

  ---

• Phase III study comparing [177Lu]Lu-PSMA-617 vs. standard of care patients with prostate cancer

  An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer 
  

  ---

• A Phase 3 study Abiraterone + Capivasertib/Placebo in Prostate Cancer

  A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
  

  ---

• A Phase 3 study of Cabozantinib + Atezolizumab in Subjects with Metastatic Castration-Resistant Pros

  A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
  

  ---

• Phase 3 Study of Niraparib in Prostate Cancer

  A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
  

  ---

• Enzalutamide +/- Pembrolizumab in Prostate Cancer

  A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  

  ---

Renal

• Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients

  An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
  

  ---

Solid Tumors

• Phase 1b study of SM08502 w/hormonal therapy or chemotherapy in subjects with advanced solid tumors

  A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors 
  

  ---

• Seribantumab in patients with NRG1+ locally advanced or metastatic solid tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---

• A Phase 2 study of Seribantumab in Patients with Solid Tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---

• A Phase 1b/2 study of XMT-1536 in solid tumors

  A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)
  

  ---

• A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors

  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  

  ---

• A Phase 1/2 Study of BLU-667 in Advanced Solid Tumors

  A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
  

  ---

• A Phase 2 study of Sacituzumab Govitecan in Solid Tumors

  A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
  

  ---

• Phase 2 Study of Erdafitinib in Solid Tumors

  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  

  ---